申请人:IM Therapeutics, Inc.
公开号:US20170273927A1
公开(公告)日:2017-09-28
Methods of treating, ameliorating, or inhibiting the development of autoimmune diseases by modulating the binding of MHC class II molecules to antigenic peptides or fragments of antigenic peptides of the autoimmune disease. The binding may be modulated by the administration of D-α-methyldopa, or pharmaceutical compositions comprising therapeutically effective amounts of D-α-methyldopa.